Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by MADDEN SECURITIES Corp

MADDEN SECURITIES Corp trimmed its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 45.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,200 shares of the medical research company's stock after selling 2,630 shares during the period. MADDEN SECURITIES Corp's holdings in Charles River Laboratories International were worth $591,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Cetera Investment Advisers lifted its stake in shares of Charles River Laboratories International by 2.4% during the second quarter. Cetera Investment Advisers now owns 9,969 shares of the medical research company's stock worth $2,059,000 after buying an additional 229 shares during the period. Livforsakringsbolaget Skandia Omsesidigt acquired a new stake in shares of Charles River Laboratories International during the third quarter worth $79,000. Exchange Traded Concepts LLC lifted its stake in shares of Charles River Laboratories International by 26.4% during the third quarter. Exchange Traded Concepts LLC now owns 6,049 shares of the medical research company's stock worth $1,191,000 after buying an additional 1,264 shares during the period. Creative Planning lifted its stake in shares of Charles River Laboratories International by 4.0% during the third quarter. Creative Planning now owns 4,672 shares of the medical research company's stock worth $920,000 after buying an additional 180 shares during the period. Finally, Wolff Wiese Magana LLC acquired a new stake in shares of Charles River Laboratories International during the third quarter worth $32,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CRL has been the subject of a number of research reports. StockNews.com downgraded shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Thursday, November 7th. TD Cowen boosted their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research report on Monday, November 11th. Bank of America decreased their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a research report on Friday, December 13th. The Goldman Sachs Group decreased their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. Finally, William Blair downgraded shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 22nd. Three analysts have rated the stock with a sell rating, fourteen have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $200.79.

Charles River Laboratories International Price Performance

Shares of CRL stock traded down $1.10 on Friday, reaching $152.07. 841,129 shares of the company were exchanged, compared to its average volume of 971,344. The company has a market cap of $7.78 billion, a price-to-earnings ratio of 19.03, a P/E/G ratio of 6.47 and a beta of 1.37. The business has a 50-day moving average price of $176.43 and a 200 day moving average price of $191.11. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $275.00.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).